Type 1 diabetes can be detected in children with a blood test by the family pediatrician long before symptoms develop or an emergency occurs, researchers reported, suggesting more widespread early screening may be in order.
Most children who developed full-blown type 1 diabetes in this study had no family history of the disease, which means screening should not be limited to those with a family history, the researchers said in a report in JAMA.
“The ability to detect type 1 diabetes early through screening and monitoring is a significant breakthrough with vast potential to reach a broad population and change the course of the disease for those who will develop it," Esther Latres of Breakthrough T1D, which helped fund the research, said in a statement.
Families often don't recognize the early-warning symptoms of diabetes such as excessive thirst, weight loss, or fatigue, leading to development of diabetic ketoacidosis, a severe medical emergency, the researchers noted.
In the study in Germany, more than 220,000 children were tested for early stages of type 1 diabetes during routine pediatric care. A small blood sample is analyzed for the presence of at least two different types of islet autoantibodies, which are immune cells that mistakenly attack the pancreas.
Children with islet autoantibodies but normal blood glucose levels are considered to be in stage 1. Families receive information, education, and access to specialized diabetes centers where regular follow-up examinations then take place.
In stage 2, the first signs of impaired glucose metabolism appear. In stage 3, insulin is required.
At the first screening, 590 children, or roughly 0.3%, were found to have early-stage type 1 diabetes. Eventually, 212 of them progressed to stage 3.
After five years, the probability of progressing from an early stage to clinical type 1 diabetes was 36.2%, researchers reported.
Once an early stage was diagnosed, there was no difference in disease progression in children with and without a family history, they noted.
“The long-standing argument that early-stage disease cannot be readily identified - and therefore cannot efficiently or effectively be studied or targeted - no longer holds,” Dr. Jamie Felton and Dr. Emily Sims of the Indiana University School of Medicine, who were not involved in the study, wrote in an editorial.
“The findings suggest that the time to seriously consider general population screening has arrived,” they concluded.